IDH1 inhibitorFDA-approvedFirst-line
Ivosidenib
How it works
Blocks the IDH1 enzyme, which is overactive in AML cells, and also inhibits other enzymes involved in cancer growth.
Cancer types
Leukemia— IDH1-mutated AML
Efficacy
In clinical trials, around 40% of IDH1-mutated patients achieved a complete remission, with a median overall survival of approximately 9 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Ivosidenib and Venetoclax for IDH1 Mutated Hematologic Malignancies | Leukemia | phase-1 | — | Source → |
| New Study Compares Effectiveness of Two Leukemia Treatments | Leukemia | phase-3 | Treatment with OLU versus IVO was associated with significantly higher rates of complete response (RD: 0.25; 95%CI: 0.01, 0.49), transfusion independence (RD: 0.27; 95%CI: 0.01, 0.53), and OS (HR: 0.33; 95%CI: 0.11, 0.94). | Source → |
| New Study Compares Effectiveness of Leukemia Treatments | Leukemia | meta-analysis | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.